PRICED Act
Summary
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
Bill status
in committee
1 of 4 stages cleared
Introduction
May 2022
Committee Review
Floor Vote
President
Introduced May 18, 2022
Last action May 18, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
May 18, 2022
Committee
Referred to the House Committee on Energy and Commerce.
lower
May 18, 2022
Introduced
Introduced in House
lower
1 primary · 10 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Janice D. Schakowsky
DDemocratic
Co
Andy Levin
DDemocratic
Co
Bruce Westerman
RRepublican
Co
Jesús G. "Chuy" García
DDemocratic
Co
Lloyd Doggett
DDemocratic
Co
Marcy Kaptur
DDemocratic
Co
Mark Pocan
DDemocratic
Co
Pramila Jayapal
DDemocratic
Co
Raja Krishnamoorthi
DDemocratic
Co
Ro Khanna
DDemocratic
Co
Rosa L. DeLauro
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 7828
Scope: US
Hi! I can help you understand HR 7828. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline